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Abstract: Background: Flavonoids potentially exert anti-cancer effects, as suggested
by their chemical structures and supported by animal studies. In observational studies,
however, the association between flavonoids and breast cancer, and potential underlying
mechanisms, remain unclear. Objective: To examine the relationship between flavonoid intake
and sex hormone levels using timed blood samples in follicular and luteal phases in the
Nurses’ Health Study II among premenopausal women. Methods: Plasma concentrations of
estrogens, androgens, progesterone, dehydroepiandrosterone (DHEA), DHEA sulfate (DHEAS),
prolactin, and sex hormone-binding globulin (SHBG) were measured in samples collected between
1996 and 1999. Average flavonoid were calculated from semiquantitative food frequency
questionnaires collected in 1995 and 1999. We used generalized linear models to calculate
geometric mean hormone concentrations across categories of the intake of flavonoids and the
subclasses. Results: Total flavonoid intake generally was not associated with the hormones of interest.
The only significant association was with DHEAS (p-trend = 0.02), which was 11.1% (95% confidence
interval (CI): −18.6%, −3.0%) lower comparing the highest vs. lowest quartile of flavonoid intake.
In subclass analyses, the highest (vs. lowest) quartile of flavan-3-ol intake was associated with
significantly lower DHEAS concentrations (−11.3% with 95% CI: −18.3%, −3.7%, p-trend = 0.01),
and anthocyanin intake was associated with a significant inverse trend for DHEA (−18.0% with 95%
CI: −27.9%, −6.7%, p-trend = 0.003). Conclusion: Flavonoid intake in this population had limited
impact on most plasma sex hormones in premenopausal women. Anthocyanins and flavan-3-ols
were associated with lower levels of DHEA and DHEAS.
Keywords: flavonoid; sex hormones; biomarker; premenopausal women; circulating hormones
1. Introduction
Flavonoids, a diverse group of polyphenols, consist of more than 5000 different compounds
produced in plants [1,2]. They have been considered one of the active components in fruits and
vegetables that have antioxidant, anti-inflammatory, and anti-proliferative properties [3].
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The initial interest in studying flavonoids stemmed from the observation that Asian populations
have higher intake of soy products, which are high in flavonoids, particularly isoflavones, and lower
breast cancer incidence rates compared to Western populations. As circulating estrogens and androgens
are positively associated with the risk for breast cancer in pre- and postmenopausal women [4–7],
flavonoids are also of special interest in relation to breast cancer due to the structural resemblance to
estrogens [8], yet its consequent risk and benefit are still controversial. In vitro studies have shown
promising anti-cancer effects of flavonoids [9]. In observational studies, however, the association is less
clear, as most significant associations have been reported in Asian populations, in case-control studies,
or for postmenopausal breast cancer, but generally not in Western populations, prospective cohort
studies, or for premenopausal breast cancer [10–12].
The discrepancies between in vitro studies and human studies suggest that flavonoids are
involved in more complex biological processes in vivo, yet the direction in which flavonoids affect
sex steroid hormone-dependent activities is far from conclusive. Soymilk that is rich in isoflavone
reduces circulating ovarian steroids and adrenal androgens and increases menstrual cycle length in
premenopausal women [13,14]; while other subclasses of flavonoid have been shown to have binding
affinities to estrogen receptor-α (ERα), and possible stimulation of ER-dependent transcriptional
response that promotes growth of estrogen-dependent cells was implicated [15–17]. The effect of total
flavonoid intake on risk of breast cancer is a combined result of the relative strengths in either direction,
as well as the overall effect of all subclasses; it is important to elucidate whether any subcalsses of
flavonoid modulate circulating estrogen and other sex hormones. To date, no study has characterized
the relationship between dietary intake of specific subclasses of flavonoids and blood sex hormone
levels as they vary over the menstrual cycle. In this study, we investigated the relationship among
premenopausal women using timed samples in both follicular and luteal phases in the Nurses’ Health
Study II (NHSII).
2. Materials and Methods
2.1. Study Population
The NHSII is a prospective cohort study established in 1989 among 116,429 female registered nurses
from 25 to 42 years of age. The enrolled women completed a questionnaire at study enrollment and are
asked biennially to update with their medical and lifestyle factors and disease diagnoses. Between 1996
and 1999, blood samples were collected among a subgroup of participants in the NHSII. Details of the
blood collection procedure are described in a prior publication [18]. Among the 29,611 participants
who donated blood, 18,521 women who were not taking oral contraceptives, pregnant, or breastfed
within 6 months providing timed samples collected in the follicular phase (3 to 5 days after the start
of the menstrual cycle) and luteal phase (an estimated 7 to 9 days prior to the onset of the next
menstrual cycle). Participants separated the plasma for the follicular sample and stored it in the freezer
until the luteal sample was collected. Participants who provided untimed samples were included in
analyses of dehydroepiandrosterone (DHEA), DHEA sulfate (DHEAS), testosterone, free testosterone,
androstenedione, sex hormone–binding globulin (SHBG), and prolactin, as the concentrations of these
hormones do not fluctuate much during menstrual cycles [19]. All blood samples were shipped
overnight with an ice pack, processed by our laboratory into plasma, red blood cells, and white blood
cells, and then stored in continuously monitored liquid nitrogen freezers (≤−130◦). The original vials
were thawed once to subaliquot a sample to send to each respective laboratory, and a second thaw
occurred at the time of assay. The collection, processing, and storage methods of blood samples in NHSII
have been shown to not materially alter levels of sex hormones. Furthermore, the between-person
variation for most of the sex hormones far outweighed their within-person variation even with up to
2 days of delay in processing after phlebotomy [20,21].
Participants included in this analysis were part of a hormone reproducibility study [19], or were
the controls in nested case-control studies of breast cancer [22], ovarian cancer [23], endometriosis [24],
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and rheumatoid arthritis [25]. A total of 2000 premenopausal women had measured concentrations of
plasma sex hormones (estradiol, estrone, estrone sulfate, progesterone, DHEA, DHEAS, testosterone,
androstenedione), prolactin, and SHBG concentrations. Among these participants, 1989 had flavonoid
consumption data available in 1995, 1999, or both. The study protocol was approved by the
Institutional Review Boards of the Brigham and Women’s Hospital and the Harvard T.H. Chan
School of Public Health.
2.2. Laboratory Assays
The laboratory assay methods used to obtain the concentrations of each hormone were documented
in prior publications [5,26]. Estrone, estradiol, and estrone sulfate concentration were assayed in
luteal and follicular samples; testosterone, androstenedione, and prolactin concentrations were
assayed in luteal and/or follicular, as well as untimed samples; DHEA, DHEAS, and SHBG were
assayed in luteal and untimed samples; and progesterone was assayed in luteal samples only.
The assays were performed in different batches at different laboratories for several different sets of
nested case-control studies. Three batches of estrogens, five batches of testosterone, two batches
of androstenedione, and one batch of progesterone were assayed at Quest Diagnostics (San Juan
Capistrano, CA, USA). At this location, estrogens and testosterone were measured by organic
extraction, celite column chromatography, and then radioimmunoassay (RIA); estrone sulfate was
measured by extraction of estrone, enzyme hydrolysis, column chromatography, and then RIA of
estrone; progesterone were measured by organic extraction and RIA. Four batches of estrogens
and testosterone were assayed at Mayo Medical Laboratories (Rochester, MN, USA) using liquid
chromatography–tandem mass spectrometry (LC-MS/MS). Two batches of DHEA and androstenedione
and four batches of DHEAS, SHBG, and progesterone were assayed at the Royal Marsden Hospital
(London, United Kingdom). At this location, androstenedione was measured by RIA; and DHEAS,
SHBG, and progesterone were measured by chemiluminescent enzyme immunoassay. One batch
of progesterone, three batches of SHBG, and prolactin were assayed at Massachusetts General
Hospital (Boston, MA, USA), where progesterone was measured by RIA, SHBG was measured by
chemiluminescent enzyme immunoassay, and prolactin was measured by microparticle enzyme
immunoassay (AxSYM Immunoassay System). One batch of SHBG and progesterone was assayed at
Boston Children’s Hospital (Boston, MA, USA). Batch correction was performed as descibed in the
statistical method section.
Free and percent free estradiol were calculated by the law of mass action according to the method
described by Sodergard et al. [27]. The detection limits of the assays were as follows: 2 pg/mL
for estradiol, 10 pg/mL for estrone, 40 pg/mL for estrone sulfate (in each laboratory), 3 ng/dL for
androstenedione, 1 ng/dL for testosterone, 3 ng/dL for DHEA, 5 µg/dL for DHEAS, and 3 ng/dL for
progesterone. When plasma hormone values were reported as less than the detection limit, we set the
value to half this limit. All plasma hormone concentrations under the detection limits were set to half
of the minimum detection value.
The reproducibility of plasma estrogens (intraclass correlation coefficients, ICC: 0.38–0.69),
androgens (ICC: 0.56–0.94), progesterone (ICC: 0.29), prolactin (ICC: 0.64), and sex hormone binding
globulin (ICC: 0.86) has been documented [19].
2.3. Exposure and Covariates Measurement
Flavonoid intake was calculated from semiquantitative food frequency questionnaires (FFQ)
administered closest to the blood collection to represent the average intake around the time between
1995 and 1999. The participants were asked to estimate their usual intake of a list of ~131 food
items, from which the intake of flavonoids were calculated using a database maintained by Harvard
dietitians (available for request at: https://regepi.bwh.harvard.edu/health/nutrition.html) that is largely
based on the United States Department of Agriculture (USDA) food content database [28]. In the
study that validated the FFQ against dietary records, the Spearman rank correlation coefficient is
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0.55 for energy-adjusted total flavonoid intake, and from 0.41 to 0.58 for flavonoid subclasses [29].
For this study, we used average energy-adjusted intake of the nutrients from 1995 and 1999, or a single
measure in 1995 or 1999 if there was only one available (n = 192). We evaluated total flavonoids
in our primary analyses. As secondary analyses, we examined 6 flavonoid subclasses-flavonols,
flavanones, flavones, flavan-3-ols, anthocyanins, and isoflavones.
From the questionnaire completed at blood collection or the questionnaire immediately prior to
blood draw, we obtained data on potential confounders for the association between flavonoid intake and
plasma sex hormone concentrations: age at blood collection, smoking status, body mass index (BMI),
height, age at menarche, usual menstrual cycle length, menstrual cycle pattern, parity, family history
of breast cancer, history of biopsy-confirmed benign breast disease, physical activity, date and time of
day of blood collection, fasting status, luteal day of blood collection, average alcohol consumption,
weight change from age 18, and total energy intake.
2.4. Statistical Analyses
Estradiol, free estradiol, estrone, and estrone sulfate were evaluated in follicular and luteal phases;
progesterone was only evaluated in luteal phase; DHEA, DHEAS, testosterone, free testosterone,
androstenedione, and prolactin were measured using the average of follicular and luteal phases or from
a single luteal or untimed sample. We identified statistical outliers in the hormone data based on the
generalized extreme studentized deviate (ESD) many-outlier detection approach [30]; the outliers were
excluded from analyses. For each of the hormones, no more than 8 outliers were excluded. To address
differences that might arise from assays being performed at multiple locations in multiple batches,
all hormones were recalibrated to have a comparable distribution between all batches using the method
of Rosner and colleagues [31,32]. In brief, we made statistical adjustment where the concentrations
were combined to represent an average batch, then regressed on age, BMI (the strongest predictor
of hormone levels), and indicator variables for each batch. Within each batch, the hormone levels
were recalibrated according to the difference between the coefficients for that batch and the average
of the batch coefficients. The adjusted concentrations thus accounted for between-batch variability
independent of varying distributions of age and BMI across batches.
In our primary analyses, we calculated the geometric mean of each hormone concentration by
quartile of total flavonoid intake using generalized linear models, with marginal covariate distribution
in the study population. A contrast comparing the highest to the lowest quartile of flavonoid intake was
also estimated. Confounders included in the models were based on subject matter knowledge and prior
literature—age at blood collection in years (continuous), BMI at blood collection in kg/m2 (<22.5, 22.5 to
<25, 25 to <27.5, 27.5 to <30, ≥30), total energy intake in kcal/day (continuous), smoking (never smoker,
past smoker with ≥5 years since quitting, past smoker with <5 years since quitting, current smoker
of <15 cigarettes per day, current smoker of 15 cigarettes per day), alcohol use (non-drinker, 10 g/day,
10.1–20 g/day, >20 g/day), physical activity (<3, 3–<9, 9–<18, 18–<27, ≥27 metabolic equivalent of
task (MET)-hours/week), duration of past oral contraceptive use (never, <4 years, ≥4 years), age at
menarche (<12, 12–13, >13 years), age at first birth/parity (nulliparous, 1–2 children and age at first
birth <25 years, 1–2 children and age at first birth ≥25 years, >3 children and age at first birth <25 years,
>3 children and age at first birth ≥25 years). Covariates related only to the outcomes—date of blood
collection (month/year, 1/97, 2/97–1/98, 2/98–1/99, after 2/99), time of day of blood collection (1–8 a.m.,
9 a.m. to noon, 1–4 p.m., 5 p.m. to midnight), and fasting status (<10, ≥10 h)—were also included in
the models to reduce extraneous variation. Models that included luteal or average of timed samples
also were adjusted for the difference between luteal blood draw date and date of next menstrual
period (3–7, 8–12, 13–17, 18–21 days, unknown/untimed). We also evaluated the linear trend of
flavonoid intake using median of each quartile modeled continuously and calculated a Wald test
statistic. In secondary analyses, we repeated the main analyses for each subclass of flavonoids-flavonols,
flavanones, flavones, flavan-3-ols, anthocyanins, and isoflavones. We also conducted a priori sensitivity
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analyses by excluding women who had luteal progesterone level <400 ng/dL (n = 230, 11.6%) to restrict
the analysis to women who donated blood samples during an ovulatory cycle.
3. Results
The mean age at blood draw of the 1989 participants was 42.7 years, and the mean BMI was
26.1 kg/m2. Flavonoid intake did not vary substantially by height, BMI at age 18 or at blood draw,
or reproductive factors. Those who had higher intake of total flavonoids tended to be more physically
active, and less likely to be current smokers (Table 1).
Table 1. Characteristics at blood draw of premenopausal women in the Nurses’ Health Study II (NHSII,
n = 1989).
Variables
Total Flavonoid Intake (mg/day)
Quartile 1 Quartile 2 Quartile 3 Quartile 4
<170.3 170.3–241.8 241.9–359.3 >359.3
n = 497 n = 496 n = 498 n = 498
Mean (SD +) Mean (SD +) Mean (SD +) Mean (SD +)
Age, years 42.3 (4.1) 42.5 (4.2) 43.0 (4.0) 43.0 (3.9)
Caucasian, % 98.0 99.0 98.2 98.0
Height, inches 64. 9 (2.7) 64.8 (2.5) 65.3 (2.5) 64.9 (2.7)
Body mass index (BMI), kg/m2 26. 6 (6.7) 26.1 (7.2) 25.2 (6.3) 26.4 (7.5)
BMI at age 18, kg/m2 21.2 (3.2) 21.3 (3.2) 20.9 (2.9) 21.1 (3.0)
Physical activity, MET*-hours/week 16.2 (7.2) 17.7 (17.3) 20.0 (18.7) 18.2 (17.2)
Current smoker, % 11.3 7.9 5.8 7.0
AHEI ** score 47.9 (9.5) 52.0 (9.8) 53.9 (10.8) 53.3 (10.7)
Total fruit intake, servings/day 1.2 (0.7) 1.95 (0.9) 2.4 (1.2) 2.2 (1.5)
Total vegetable intake, servings/day 3.1 (1.8) 3.7 (1.9) 4.0 (2.1) 4.0 (2.3)
Age at menarche <12 years, % 23.7 19.6 19.1 25.3
Usual menstrual cycle pattern regular, % 93.1 89.5 92.2 92.7
Parity 2.4 (0.96) 2.3 (0.97) 2.3 (0.93) 2.3 (0.92)
Parous, % 83.7 82.6 76.3 80.5
Age at first birth among parous women, years 26.4 (4.2) 26.7 (4.7) 26.9 (4.4) 26.7 (4.5)
Past breastfeeding history, % 67.8 69.2 64.5 69.5
Past oral contraceptive use, % 86.9 83.7 83.5 86.1
Family history of breast cancer, % 9.3 11.1 9.0 8.2
Benign breast disease history (biospy confirmed), % 16.1 16.9 18.9 16.1
* MET, metabolic equivalent of task, an objective measure of the ratio of the rate at which a person expends energy,
relative to the mass of that person while performing some specific physical activity compared to a reference energy
expended when sitting quietly (roughly at 3.5 mL of oxygen per kilogram per minute); ** AHEI, the Alternative
Healthy Eating Index, ranging from 0 to10 points. A score of 10 indicates that the recommendations were fully met,
whereas a score of 0 represents the least healthy dietary behavior. + Unless otherwise stated. SD, standard deviation.
Table 2 shows the median concentration and 10th–90th percentile of the plasma sex hormones,
prolactin, and SHBG. The Spearman rank correlation coefficients between the concentrations of the
hormones, prolactin, and SHBG ranged from 0.0007 for follicular estradiol and androstenedione, to 0.88
for follicular estradiol and follicular-free estradiol.
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Table 2. Plasma hormone concentrations among premenopausal women in the NHSII (n = 1989).
Plasma Hormone n Median 10th Pctl–90th Pctl
Follicular estradiol, pg/mL 1397 46.8 22.1–101
Luteal estradiol, pg/mL 1524 134 72.5–237
Follicular free estradiol, pg/mL 1361 0.59 0.3–1.18
Luteal free estradiol, pg/mL 1508 1.69 0.93–2.86
Follicular estrone, pg/mL 1417 40.6 25–67.7
Luteal estrone, pg/mL 1571 84.2 51.1–142
Follicular estrone sulfate, pg/mL 444 661 299–1517
Luteal estrone sulfate, pg/mL 449 1454 573–3326
Luteal progesterone, ng/dL 1587 1396 251–2696
DHEA *, ng/dL 476 614 346–1127
DHEAS *, µg/dL 1240 86.8 39.5–163
Testosterone +, ng/dL 1956 23.5 14.2–36.8
Free testosterone +, ng/dL 1898 0.20 0.1–0.37
Androstenedione +, ng/dL 623 100 60.2–164
Prolactin +, ng/dL 1300 14.5 8.24–28.7
SHBG +, nmol/L 1916 64.5 32.4–116
* Include luteal or untimed samples. DHEA: dehydroepiandrosterone; DHEAS: dehydroepiandrosterone sulfate.
+ Include average of follicular and luteal samples, or untimed samples. SHBG: sex hormone-binding globulin.
In our study, the major sources of food for flavonoids were tea and apples, making up over 50% of
the total flavonoid intake. The top contributing food items for the six flavonoid subclasses were flavonol
(tea and onions), flavone (orange and orange juice), flavanone (orange and orange juice), flavan-3-ol (tea
and apples), anthocyanin (blueberries and strawberries), isoflavone (tofu and soymilk) (Table S3).
Flavna-3-ol had foods with the highest intake among the six subclasses. The correlations between the
subclasses of flavonoid are shown in Supplemental Table S1. Flavonol and flavan-3-ol intakes were
highly correlated, and since flavan-3-ol had the highest intake level, both were also highy correlated
with total flavonoid intake (Spearman correlation coefficients 0.75–0.97, p < 0.0001). The correlations
between other pairs of flavonoids subclasses were relatively weak (Spearman correlation coefficients
<0.25) (Supplementary Materials Table S1).
In this study, total flavonoid intake was not significantly associated with any of the sex hormone
concentrations except for DHEAS (p = 0.02); plasma DHEAS was 11.1% lower comparing the highest
vs the lowest quartile of flavonoid intake (95% confidence interval (CI): −18.6%, −3.0%) (Table 3).
The percent difference comparing the highest versus the lowest quartile for the remaining sex hormones
ranged from −7.4% to 5.1%.
In secondary analyses, we examined the six subclasses of flavonoids. Similar to total flavonoids,
only DHEA and DHEAS showed significant differences between the extreme quartiles of the intake
of the subclasses of flavonoid (Table 4). Interestingly, DHEAS was significantly lower (−11.3%
with 95% CI: −18.3, −3.7%, p-trend = 0.01) comparing the extreme quartiles of flavan-3-ol intake,
however in contrast, DHEAS tended to increase significantly across quartiles of flavanone intake,
although the difference between the highest and the lowest quartiles were only marginally significant
(9.0% with 95% CI: −0.3%, 19.3%, p-trend = 0.04). Across the quartiles of flavan-3-ol intake,
luteal progesterone concentration showed a significant increasing trend (p = 0.03), although the
contrast between the highest and the lowest quartile was not statistically significant (−7.6%, 95% CI:
−14.78%, 0.20%). Anthocyanin intake was associated with significant inverse trends for DHEA (−18.0%
with 95% CI: −27.9%, −6.7%, p-trend = 0.003) and follicular estrone sulfate, although the contrast
between the extreme quartiles was not statistically significant for follicular estrone sulfate (−16.9% with
95% CI: −32.5%, 2.4%, p-trend = 0.02). Hormones with concentrations significantly higher comparing
the highest and the lowest quartile of isoflavone were follicular estrone sulfate (25.7% with 95% CI:
3.6%, 52.6%) and DHEAS (12.7% with 95% CI: 3.5%, 22.8%), although neither had significant linear
trend across quartiles of isoflavone intake.
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Table 3. Adjusted 1 geometric mean concentration 2 of hormones by categories of average flavonoid consumption among 1989 premenopausal women in the NHSII.
Total Flavonoid Intake, mg/day
Hormone n Quartile 1 Quartile 2 Quartile 3 Quartile 4 p-Trend 3
Percentage Difference 4
and 95% Confidence Interval
(CI)
Range <170.3 170.3–241.8 241.9–359.3 >359.3 Mean 95% CI
Median Flavonoid intake 128.0 204.9 288.2 550.2
Follicular estradiol, pg/mL 1397 77.8 79.3 75.5 75.8 0.53 −2.6% (−13.4%, 9.5%)
Luteal estradiol, pg/mL 1524 129.8 134.9 129.1 129.6 0.65 −0.1% (−6.9%, 7.2%)
Follicular free estradiol, pg/mL 1361 0.79 0.82 0.75 0.78 0.60 −0.9% (−10.0%, 9.1%)
Luteal free estradiol, pg/mL 1508 1.58 1.68 1.59 1.59 0.60 0.4% (−6.8%, 8.1%)
Follicular estrone, pg/mL 1417 47.3 46.5 47.1 46.7 0.84 −1.2% (−8.1%, 6.2%)
Luteal estrone, pg/mL 1571 81.2 81.6 82.0 79.4 0.38 −2.2% (−8.3%, 4.3%)
Follicular estrone sulfate, pg/mL 444 777.1 773.2 785.1 795.1 0.77 2.3% (−16.3%, 25.1%)
Luteal estone sulfate, pg/mL 449 1511.2 1379.4 1761.3 1404.5 0.51 −7.1% (−24.8%, 14.8%)
Luteal progesterone, ng/dL 1587 1135.5 1112.5 1130.8 1051.1 0.06 −7.4% (−14.6%, 0.4%)
DHEA, ng/dL 386 841.1 797.7 823.9 855.3 0.55 1.7% (−11.0%, 16.2%)
DHEAS, µg/dL 1083 107.0 98.4 102.7 95.1 0.02 −11.1% (−18.6%, −3.0%)
Testosterone, ng/dL 1956 24.3 24.5 24.8 24.4 0.97 0.5% (−4.2%, 5.4%)
Free testosterone, ng/dL 1898 0.20 0.21 0.20 0.20 0.26 −2.1% (−8.6%, 4.9%)
Androstenedione, ng/dL 623 130.9 123.8 130.0 129.1 0.92 −1.4% (−9.6%, 7.6%)
Prolactin, ng/dL 1300 22.0 21.9 21.7 23.1 0.25 5.1% (−5.5%, 16.8%)
SHBG, nmol/L 1675 75.5 74.8 76.2 78.5 0.11 3.9% (−1.9%, 10.1%)
1 Covariates in the model: race, height, age at blood draw, BMI at blood draw, smoking status, alcohol consumption, parity, age at first birth, age at menarche, usual menstrual cycle length,
menstrual cycle pattern, family history of breast cancer, history of biopsy-confirmed benign breast disease, duration of oral contraceptive use, physical activity, luteal day difference
(number of days with reference to beginning of next menstruation), total calories, blood draw date, blood draw time of the day, and fasting status at blood draw. 2 Geometric mean
concentration calculated as the expected hormone or other biomarker levels within each quartile of flavonoid intake, based on the multivariate model where the other covariates are set to
the distribution at the population level in the study. 3 The cut-off p-value for statistical significance is 0.003 if considering multiple testing (α = 0.05). 4 Percentage difference: the difference
in geometric mean concentration of the hormones between the top versus the bottom quartile presented as percentages of the bottom quartile.
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Table 4. Adjusted geometric mean concentration of hormones by categories of average consumption of flavonoid subclasses among premenopausal women in the
NHSII (n = 1989).
Hormones
Flavonol Intake, mg/day
Quartile1 Quartile2 Quartile3 Quartile4 p-Trend Percentage Difference and 95% CI
2.8–10.9 10.9–14.9 15.0–21.2 >21.2 Mean 95% CI
Median 8.6 12.9 17.5 28.5
Follicular estradiol, pg/mL 76.9 78.0 79.7 74.1 0.50 −3.7% (−15.7%, 10.1%)
Luteal estradiol, pg/mL 133.2 130.8 127.0 132.2 0.93 −0.7% (−8.1%, 7.2%)
Follicular free estradiol, pg/mL 0.77 0.81 0.79 0.77 0.72 0.0% (−9.3%, 10.3%)
Luteal free estradiol, pg/mL 1.61 1.65 1.57 1.61 0.72 −0.2% (−7.8%, 8.0%)
Follicular estrone, pg/mL 46.4 47.8 47.2 46.4 0.79 0.1% (−7.0%, 7.8%)
Luteal estrone, pg/mL 82.1 81.7 80.3 79.9 0.38 −2.8% (−9.1%, 4.0%)
Follicular estrone sulfate, pg/mL 824.9 753.4 738.9 786.1 0.89 −4.7% (−23.2%, 18.3%)
Luteal estone sulfate, pg/mL 1497.9 1565.0 1608.9 1445.1 0.55 −3.5% (−21.1%, 18.0%)
Luteal progesterone, ng/dL 1110.1 1146.1 1101.2 1081.7 0.31 −2.6% (−10.3%, 5.8%)
DHEA, ng/dL 813.0 853.1 846.7 854.6 0.61 5.1% (−9.6%, 22.2%)
DHEAS, µg/dL 101.3 103.3 103.0 98.2 0.34 −3.1% (−11.5%, 6.2%)
Testosterone, ng/dL 24.3 24.8 24.7 24.3 0.80 0.0% (−4.9%, 5.2%)
Free testosterone, ng/dL 0.20 0.21 0.20 0.20 0.69 −0.4% (−7.8%, 7.7%)
Androstenedione, ng/dL 128.2 130.2 131.3 129.4 0.89 0.9% (−8.2%, 10.9%)
Prolactin, ng/dL 22.5 20.9 22.2 23.0 0.33 2.0% (−8.4%, 13.6%)
SHBG, nmol/L 77.4 72.6 75.9 78.3 0.30 1.2% (−5.6%, 8.5%)
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Table 4. Cont.
Flavanone Intake, mg/day
Quartile1 Quartile2 Quartile3 Quartile4 p-Trend Percentage Difference and 95% CI
0.05–14.9 14.9–27.4 27.4–47.4 >47.4 Mean 95% CI
Median 9.0 21.0 35.9 66.6
Follicular estradiol, pg/mL 75.0 78.2 74.5 79.7 0.52 6.3% (−7.8%, 22.5%)
Luteal estradiol, pg/mL 135.6 125.5 128.4 134.9 0.60 −0.5% (−8.3%, 8.0%)
Follicular free estradiol, pg/mL 0.70 0.82 0.83 0.79 0.16 11.8% (1.5%, 23.2%)
Luteal free estradiol, pg/mL 1.68 1.55 1.60 1.62 0.77 −3.5% (−11.0%, 4.7%)
Follicular estrone, pg/mL 46.2 46.2 48.2 47.3 0.40 2.4% (−4.5%, 9.7%)
Luteal estrone, pg/mL 84.7 76.6 80.0 83.3 0.62 −1.7% (−7.8%, 4.9%)
Follicular estrone sulfate, pg/mL 741.2 757.5 779.6 869.8 0.11 17.4% (−5.4%, 45.5%)
Luteal estone sulfate, pg/mL 1582.9 1342.3 1479.6 1611.8 0.50 1.8% (−17.8%, 26.1%)
Luteal progesterone, ng/dL 1089.4 1110.2 1119.5 1122.4 0.52 3.0% (−5.4%, 12.2%)
DHEA, ng/dL 864.0 841.6 836.3 805.5 0.30 −6.8% (−18.3%, 6.3%)
DHEAS, µg/dL 98.0 99.2 102.3 106.9 0.04 9.0% (−0.3%, 19.3%)
Testosterone, ng/dL 24.6 24.4 24.2 24.9 0.63 1.0% (−4.2%, 6.4%)
Free testosterone, ng/dL 0.20 0.20 0.20 0.20 0.89 0.1% (−6.3%, 7.0%)
Androstenedione, ng/dL 128.4 128.0 132.3 129.8 0.74 1.2% (−7.7%, 10.8%)
Prolactin, ng/dL 22.1 21.9 22.8 21.4 0.56 −3.3% (−12.0%, 6.3%)
SHBG, nmol/L 79.8 77.0 72.7 76.1 0.14 −4.7% (−10.5%, 1.4%)
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Table 4. Cont.
Flavone Intake, mg/d
Quartile1 Quartile2 Quartile3 Quartile4 p-Trend Percentage Difference and 95% CI
0.1–1.1 1.1–1.6 1.6–2.3 >2.3 Mean 95% CI
Median 0.8 1.3 1.9 3.0
Follicular estradiol, pg/mL 81.7 75.2 69.7 82.3 0.82 0.7% (−13.5%, 17.3%)
Luteal estradiol, pg/mL 133.4 125.5 127.8 136.1 0.35 2.0% (−6.4%, 11.2%)
Follicular free estradiol, pg/mL 0.74 0.82 0.77 0.81 0.24 9.5% (−0.7%, 20.9%)
Luteal free estradiol, pg/mL 1.67 1.54 1.59 1.63 0.98 −2.0% (−10.5%, 7.4%)
Follicular estrone, pg/mL 47.0 46.3 46.0 48.4 0.35 2.9% (−4.0%, 10.3%)
Luteal estrone, pg/mL 83.4 77.4 78.9 84.2 0.35 0.9% (−5.7%, 7.9%)
Follicular estrone sulfate, pg/mL 747.9 793.5 794.3 810.1 0.50 8.3% (−10.5%, 31.1%)
Luteal estone sulfate, pg/mL 1434.7 1563.9 1473.7 1694.5 0.12 18.1% (−2.7%, 43.4%)
Luteal progesterone, ng/dL 1070.2 1118.1 1114.1 1135.8 0.23 6.1% (−2.7%, 15.8%)
DHEA, ng/dL 892.3 856.0 813.2 789.4 0.06 −11.5% (−22.4%, 0.9%)
DHEAS, µg/dL 97.6 100.9 102.3 105.5 0.10 8.1% (−1.4%, 18.5%)
Testosterone, ng/dL 24.7 24.1 24.4 24.9 0.57 0.8% (−4.3%, 6.2%)
Free testosterone, ng/dL 0.20 0.20 0.20 0.20 0.92 −0.5% (−7.1%, 6.5%)
Androstenedione, ng/dL 128.7 128.9 133.6 128.7 0.94 0.0% (−9.1%, 10.0%)
Prolactin, ng/dL 22.2 22.1 22.5 21.8 0.66 −2.2% (−11.0%, 7.4%)
SHBG, nmol/L 79.7 76.2 73.1 75.9 0.18 −4.8% (−11.0%, 1.9%)
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Table 4. Cont.
Flavan-3-ol Intake, mg/day
Quartile1 Quartile2 Quartile3 Quartile4 p-Trend Percentage Difference and 95% CI
1.84–13.8 13.8–23.2 23.2–47.3 >47.3 Mean 95% CI
Median 10.2 17.5 31.9 92.5
Follicular estradiol, pg/mL 77.9 74.9 82.3 75.3 0.62 −3.3% (−14.2%, 9.0%)
Luteal estradiol, pg/mL 133.1 127.3 132.9 127.5 0.38 −4.2% (−10.9%, 3.0%)
Follicular free estradiol, pg/mL 0.81 0.79 0.75 0.77 0.43 −4.7% (−14.0%, 5.6%)
Luteal free estradiol, pg/mL 1.62 1.58 1.64 1.58 0.61 −2.3% (−9.4%, 5.4%)
Follicular estrone, pg/mL 47.3 47.1 46.2 47.0 0.95 −0.7% (−7.9%, 7.1%)
Luteal estrone, pg/mL 81.1 81.0 83.4 78.8 0.23 −2.9% (−8.7%, 3.4%)
Follicular estrone sulfate, pg/mL 774.6 762.4 722.1 820.0 0.37 5.9% (−12.9%, 28.7%)
Luteal estone sulfate, pg/mL 1435.9 1558.6 1641.4 1471.5 0.75 2.5% (−16.1%, 25.2%)
Luteal progesterone, ng/dL 1130.2 1121.9 1131.1 1044.5 0.03 −7.6% (−14.8%, 0.2%)
DHEA, ng/dL 814.2 817.5 823.9 897.8 0.11 10.3% (−4.5%, 27.3%)
DHEAS, µg/dL 107.5 100.8 99.1 95.4 0.01 −11.3% (−18.3%, −3.7%)
Testosterone, ng/dL 24.2 24.6 24.9 24.1 0.48 −0.5% (−5.2%, 4.3%)
Free testosterone, ng/dL 0.20 0.21 0.20 0.20 0.49 −0.4% (−7.2%, 6.8%)
Androstenedione, ng/dL 128.9 126.1 129.9 131.2 0.50 1.8% (−6.3%, 10.5%)
Prolactin, ng/dL 22.22 21.60 21.36 23.07 0.23 3.8% (−6.4%, 15.1%)
SHBG, nmol/L 76.2 72.2 77.7 78.1 0.10 2.5% (−3.4%, 8.8%)
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Table 4. Cont.
Anthocyanin Intake, mg/day
Quartile1 Quartile2 Quartile3 Quartile4 p-Trend Percentage Difference and 95% CI
0.24–5.4 5.4–10.2 10.2–17.2 >17.2 Mean 95% CI
Median 3.5 7.7 13.4 23.5
Follicular estradiol, pg/mL 80.7 74.8 75.6 76.5 0.61 −5.3% (−18.5%, 10.1%)
Luteal estradiol, pg/mL 128.3 135.0 131.3 127.7 0.51 −0.5% (−8.0%, 7.6%)
Follicular free estradiol, pg/mL 0.80 0.79 0.78 0.74 0.14 −7.3% (−16.5%, 2.9%)
Luteal free estradiol, pg/mL 1.60 1.66 1.61 1.55 0.22 −3.3% (−11.1%, 5.2%)
Follicular estrone, pg/mL 46.8 47.8 47.9 44.4 0.09 −5.0% (−11.7%, 2.1%)
Luteal estrone, pg/mL 76.8 84.3 82.0 80.0 0.78 4.1% (−2.3%, 10.9%)
Follicular estrone sulfate, pg/mL 816.0 843.8 789.2 678.3 0.02 −16.9% (−32.5%, 2.4%)
Luteal estone sulfate, pg/mL 1375.6 1733.9 1491.5 1454.5 0.69 5.7% (−11.8%, 26.7%)
Luteal progesterone, ng/dL 1074.6 1156.7 1123.6 1080.7 0.63 0.6% (−7.7%, 9.5%)
DHEA, ng/dL 922.7 841.1 822.3 757.0 0.003 −18.0% (−27.9%, −6.7%)
DHEAS, µg/dL 99.4 104.3 100.1 100.4 0.85 1.0% (−8.3%, 11.3%)
Testosterone, ng/dL 24.3 24.4 24.4 25.1 0.19 3.3% (−1.8%, 8.6%)
Free testosterone, ng/dL 0.20 0.20 0.21 0.20 0.41 −2.8% (−9.6%, 4.5%)
Androstenedione, ng/dL 132.4 130.8 131.8 125.0 0.18 −5.6% (−13.6%, 3.2%)
Prolactin, ng/dL 22.0 23.6 21.7 21.6 0.31 −1.9% (−11.4%, 8.6%)
SHBG, nmol/L 76.5 74.9 76.4 77.4 0.48 1.2% (−5.1%, 7.9%)
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Table 4. Cont.
Isoflavone Intake, mg/day
Quartile1 Quartile2 Quartile3 Quartile4 p-Trend Percentage Difference and 95% CI
0.04–0.27 0.27–0.43 0.43–0.88 >0.88 Mean 95% CI
Median 0.2 0.3 0.5 2.2
Follicular estradiol, pg/mL 75.3 77.6 80.4 76.4 0.84 1.5% (−12.5%, 17.9%)
Luteal estradiol, pg/mL 129.1 135.4 131.6 126.9 0.20 −1.7% (−8.6%, 5.7%)
Follicular free estradiol, pg/mL 0.78 0.77 0.81 0.78 0.93 1.1% (−8.4%, 11.5%)
Luteal free estradiol, pg/mL 1.62 1.65 1.61 1.54 0.10 −4.8% (−12.5%, 3.7%)
Follicular estrone, pg/mL 47.6 45.1 48.4 46.3 0.61 −2.9% (−9.2%, 3.9%)
Luteal estrone, pg/mL 80.8 81.9 81.7 79.7 0.41 −1.4% (−7.4%, 5.0%)
Follicular estrone sulfate, pg/mL 700.9 833.7 817.9 881.1 0.12 25.7% (3.6%, 52.6%)
Luteal estone sulfate, pg/mL 1481.1 1478.6 1554.6 1600.4 0.44 8.1% (−13.0%, 34.2%)
Luteal progesterone, ng/dL 1067.1 1105.0 1156.1 1134.8 0.39 6.3% (−2.2%, 15.7%)
DHEA, ng/dL 867.7 773.8 904.5 775.2 0.09 −10.7% (−21.4%, 1.5%)
DHEAS, µg/dL 93.5 102.7 109.0 105.4 0.14 12.7% (3.5%, 22.8%)
Testosterone, ng/dL 24.7 23.8 25.2 24.1 0.42 −2.4% (−7.2%, 2.7%)
Free testosterone, ng/dL 0.21 0.19 0.21 0.20 0.35 −4.2% (−11.5%, 3.7%)
Androstenedione, ng/dL 131.0 122.4 132.4 130.0 0.79 −0.8% (−9.3%, 8.5%)
Prolactin, ng/dL 22.9 21.5 21.7 22.2 0.96 −3.0% (−12.4%, 7.3%)
SHBG, nmol/L 75.9 77.2 74.9 76.9 0.66 1.3% (−4.8%, 7.8%)
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In sensitivity analyses excluding anovulatory women (11.3%, n = 203), the results did not change
materially. Total flavonoid intake remained significantly associated with DHEAS (p-trend = 0.04).
Among the six subclasses of flavonoids, associations that remained significant were between and
flavan-3-ols and DHEAS (p-trend = 0.03), and between anthocyanins and DHEA (p-trend = 0.01).
4. Discussion
In this study of 1989 premenopausal women, we did not observe strong associations between
intake of total flavonoids and/or its subclasses and most of the sex hormones examined. The only
significant trends were that women with higher flavonoid intakes, especially that of flavan-3-ol and
anthocyanins, had lower plasma DHEA and DHEAS concentrations; this has been associated with
decreased risk of premenopausal breast cancer in the same cohort [33], as well as in a large pooled
analysis [6].
Flavonoids in general have been considered as phytochemicals with the potential for antioxidant
and anti-inflammatory activity [34,35], although the antioxidant capacity is limited after extensive
metabolism that is sufficient to reduce plasma indices of oxidant status in vivo. In vitro studies suggest
that they also have the promise as anti-tumor agents [3]-a number of flavonoids can induce apoptosis in
cancer (including breast cancer) cell lines, arreste proliferation at the G2/M cell cycle checkpoint [36,37],
and bound strongly with Estrogen Receptor β, (ER-β), which opposes the proliferative effects of ERα
activation [38]. However, due to their estrogenic feature, some flavonoids also have binding affinity to
ER-α, indicating possible promotion of proliferation [16]. The health benefit of even the most promising
subclass-isoflavone-was challenged, given that soy isoflavone extracts may promote estrogen receptor
positive breast cancer cell growth [39]. In addition, the majority of the evidence from lab-based
experimental studies did not take into consideration the absorption and metabolic interactions within
the human body. Epidemiologic studies that examined the relationship between flavonoids (dietary
intake and circulating concentrations, as well as urinary levels) and breast cancer risk among humans
have shown inconsistent results so far [11]. For example, short-term supplementation of soymilk
rich in isoflavones decreased circulating estrogens among premenpausal women, and isoflavones
were associated with lower premenopausal breast cancer risk in Asian and German populations [40].
However, studies also suggest that soy (the main source of isoflavone) supplementation may increase
the expression of several tumor-promoting genes [41], and the breast cancer risk reduction by isoflavone
was not seen in most Western countries.
A meta-analysis published in 2013 synthesized multiple prospective cohort and case-control studies
on flavonoid intake and breast cancer risk. While total flavonoid intake, especially that of flavonols and
flavones, was inversely associated with postmenopausal breast cancer, the results for premenopausal
women were non-significant [42]. Among all proposed effects of flavonoid, most (e.g., antioxidation,
anti-inflammation, inhibition of carcinogen-activating enzymes) are independent of menopausal status.
What is most plausible to explain the different effects of flavonoid on pre and postmenopausal breast
cancer is the complicated interaction between flavonoid and sex hormones. One may be concerned
that flavonoids might alter sex hormones in premenopausal women in the undesired direction thus
counteract the overall benefit. Our results are reassuring that flavonoids are not associated with higher
concentrations of circulating sex hormones. In fact, DHEA and DHEAS demonstrated inverse linear
trends with higher intake of anthocyanins and flavan-3-ols. In vitro studies have shown that DHEA
increases proliferation in the human breast cancer cell line MCF-7 at physiological concentrations
and has an antiproliferative effect at supraphysiologic concentrations [43–46]. DHEAS also has the
potential to induce growth of ER-positive/AR-positive cells [47].
It is possible that a greater range of intake would result in further reduction of the hormones,
and may lead to a decreased risk of breast cancer. In contrast, flavanones were associated with
higher circulating DHEAS level. The higher intake of flavanones (median = 27.41 mg/d) compared to
flavan-3-ols (median = 23.16 mg/d) and anthocyanins (median = 10.18 mg/d), may partially offset the
lower concentrations shown with higher anthocyanin and flavan-3-ol intake, and more importantly
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emphasizes that the subclasses should be analyzed separately. Nevertheless, alternative mechanisms
are needed to explain the heterogeneity due to menopausal status. Circulating sex hormone levels
are relatively high before menopause, and therefore the degree to which dietary flavonoids can act
against endogenous sex hormones may be limited; whereas after estrogen levels fall at menopause,
the protective effect of flavonoids may become more evident.
Our study has several strengths. In a large sample of premenopausal women we assessed the
association between multiple sex hormones and flavonoid intake by subclasses. The sex hormones that
fluctuate during the menstrual cycle were timed, that is, measured in both follicular and luteal phases,
adding accuracy to the analyses. We were also able to take advantage of high-quality dietary assessment
based on validated FFQ, and had detailed data on a range of potentially important covariates. There are
also limitations of our study. Measurement errors in the assessment of flavonoid intake could attenuate
the associations, if any; meanwhile, the nutrient calculations for food items using the United States
Department of Agriculture (USDA) food content database is imperfect. However, the relative accuracy
of the exposures in our study is acceptable, since validation of FFQ versus 7-day dietary records
suggested that the questionnaire was able to represent the average intake over the yearly period.
The measurement error of the sex hormones examined should also be considered. The validity
depends on both the assays performed at different labs and the reproducibility of a single measure.
Notably, DHEAS, DHEA, and SHBG had the highest ICC among all hormones we assessed. The true
associations between flavonoid intake and the other hormones (with lower ICCs) could have been
undetectable because they were attenuated by random within-person variation. For samples that were
untimed, the Spearman correlations between samples collected during the follicular and luteal phase
were 0.60 for DHEA, 0.82 for DHEAS, 0.63 for testosterone, 0.55 for prolactin, and 0.86 for SHBG in this
population. Therefore, any fluctuation might also have attenuated the observed association. We did
not perform formal multiple testing adjustment, but given the number of statistical tests we conducted,
some of the significant associations could be due to chance. If adjusted for multiple comparisons of the
hormones, only the association between anthocyanins and DHEA would remain significant. We were
also not able to control for all potential confounders, such as other nutrients rich in fruits and vegetables.
However, in our study, the Pearson correlation coefficients between total flavonoid intake and intake
of dietary fiber, carotenoids, total fruit, and total vegetables range from 0.06 to 0.11, suggesting that
confounding by these nutrients/foods seems unlikely. Our subclass analyses, though, suggest that
most of the significant association between flavonoids and DHEAS was driven by flavan-3-ol, which is
enriched in tea [48,49]. However, in our study, the geometric mean concentrations of the biomarkers of
interest did not change significantly by quartiles of tea consumption (Supplementary Materials Table
S2), indicating that there is little chance that the observed associations in our analyses was due to other
substances in tea. Finally, this is a cross-sectional study by nature, therefore we cannot assess causality.
In conclusion, our study suggests that usual intake of total flavonoids at levels seen in this
population had limited impact on circulating sex hormones in premenopausal women. Intake of
anthocyanins and flavan-3-ols was associated with lower levels of DHEA and DHEAS, while it
is important that the subclasses of flavonoid be considered separately as they may affect sex
hormones differently.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/11/2669/s1:
Table S1: Pearson correlation coefficients of flavonoid subclasses. Table S2: Adjusted geometric mean concentration
of hormones by categories of tea consumption in 1989 premeopausal women in NHSII. Table S3: Main food
sources of total flavonoid and flavonoid subclasses in NHSII.
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